In particular, this trial evaluated the hypothesis that the risk of major adverse cardiovascular events or cancers, excluding non-melanoma skin cancer, would not be at least 1.8 times higher with tofacitinib (combined doses of 5 mg and 10 mg twice daily) than with a TNF inhibitor. This evidence concerns the gene TNF and cancer.